Biofrontera (NASDAQ:BFRI) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Biofrontera (NASDAQ:BFRI) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Wall Street Zen raised Biofrontera to a “hold” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Biofrontera Stock Performance

BFRI stock opened at $1.22 on Monday. The company has a 50-day simple moving average of $1.03 and a 200 day simple moving average of $0.96. The company has a market capitalization of $15.62 million, a P/E ratio of -1.26 and a beta of 0.78. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.27.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Thursday, May 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.29). Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. The company had revenue of $10.08 million for the quarter, compared to analyst estimates of $10.25 million. Sell-side analysts predict that Biofrontera will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. grew its position in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 976,448 shares of the company’s stock after buying an additional 332,055 shares during the quarter. Biofrontera makes up approximately 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest position. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.